9781604272147 - decision analysis and portfolio management in the biopharma industry: a practitioner’s guide von bayney, richard; orellana, jose (8 Ergebnisse)
- Hardcover
Anbieter: Rarewaves USA, OSWEGO, IL, USARarewaves USA
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 112,04
Versand gratisVersand innerhalb von USAAnzahl: Mehr als 20 verfügbar
Hardback. Zustand: New. Biopharmaceutical RandD stands at a crossroads. Escalating development costs, persistent clinical attrition, heightened competitive pressures, mounting regulatory complexity, and uncertain commercial rewards have made ""doing more with less""; an inherently flawed strategy for success and sustainability.…This one-of-a-kind book reframes the conversation, arguing that the true objective is not simply value creation, but value maximization under risk and uncertainty. By integrating decision analysis with enterprise portfolio management, it provides leaders with the intellectual and operational foundation required to make defensible, high-stakes investment decisions across drug discovery, clinical development, regulatory approval, and commercialization. Grounded in decades of real-world experience, the book builds on CREOPM, first introduced in 2012, as a pragmatic and maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of RandD organizations. Moving beyond weak data gathering resulting in single-point estimates and deterministic scorecards, it demonstrates how probabilistic modeling, efficient-frontier thinking, and integrated evaluation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking sustained competitiveness, transparent decision lineage, and measurable performance improvement in complex Biopharma environments.
- Hardcover
Anbieter: Grand Eagle Retail, Bensenville, IL, USAGrand Eagle Retail
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 112,05
Versand gratisVersand innerhalb von USAAnzahl: 1 verfügbar
Hardcover. Zustand: new. Hardcover. Biopharmaceutical R&D stands at a crossroads. Escalating development costs, persistent clinical attrition, heightened competitive pressures, mounting regulatory complexity, and uncertain commercial rewards have made ""doing more with less""; an inherently flawed strategy for success and sustai…nability. This one-of-a-kind book reframes the conversation, arguing that the true objective is not simply value creation, but value maximization under risk and uncertainty. By integrating decision analysis with enterprise portfolio management, it provides leaders with the intellectual and operational foundation required to make defensible, high-stakes investment decisions across drug discovery, clinical development, regulatory approval, and commercialization. Grounded in decades of real-world experience, the book builds on CREOPM, first introduced in 2012, as a pragmatic and maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of R&D organizations. Moving beyond weak data gathering resulting in single-point estimates and deterministic scorecards, it demonstrates how probabilistic modeling, efficient-frontier thinking, and integrated evaluation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking sustained competitiveness, transparent decision lineage, and measurable performance improvement in complex Biopharma environments. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.
- Hardcover
Anbieter: Revaluation Books, Exeter, Vereinigtes KönigreichRevaluation Books
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 135,98
EUR 14,58 VersandVersand von Vereinigtes Königreich nach USAAnzahl: 1 verfügbar
Hardcover. Zustand: Brand New. 340 pages. 7.00x0.90x10.00 inches. In Stock.
- Hardcover
Anbieter: moluna, Greven, Deutschlandmoluna
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 104,37
EUR 48,99 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
Zustand: New.
- Hardcover
Anbieter: Rarewaves USA United, OSWEGO, IL, USARarewaves USA United
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 136,40
EUR 43,36 VersandVersand innerhalb von USAAnzahl: Mehr als 20 verfügbar
Hardback. Zustand: New. Biopharmaceutical RandD stands at a crossroads. Escalating development costs, persistent clinical attrition, heightened competitive pressures, mounting regulatory complexity, and uncertain commercial rewards have made ""doing more with less""; an inherently flawed strategy for success and sustainability.…This one-of-a-kind book reframes the conversation, arguing that the true objective is not simply value creation, but value maximization under risk and uncertainty. By integrating decision analysis with enterprise portfolio management, it provides leaders with the intellectual and operational foundation required to make defensible, high-stakes investment decisions across drug discovery, clinical development, regulatory approval, and commercialization. Grounded in decades of real-world experience, the book builds on CREOPM, first introduced in 2012, as a pragmatic and maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of RandD organizations. Moving beyond weak data gathering resulting in single-point estimates and deterministic scorecards, it demonstrates how probabilistic modeling, efficient-frontier thinking, and integrated evaluation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking sustained competitiveness, transparent decision lineage, and measurable performance improvement in complex Biopharma environments.
- Hardcover
Anbieter: Kennys Bookstore, Olney, MD, USAKennys Bookstore
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 201,44
EUR 9,10 VersandVersand innerhalb von USAAnzahl: 10 verfügbar
Zustand: New. 2026. hardcover. . . . . . Books ship from the US and Ireland.
- Hardcover
Anbieter: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrlandKennys Bookshop and Art Galleries Ltd.
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 231,74
EUR 9,50 VersandVersand von Irland nach USAAnzahl: 10 verfügbar
Zustand: New. 2026. hardcover. . . . . .
- Hardcover
Anbieter: AussieBookSeller, Truganina, VIC, AustralienAussieBookSeller
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 217,74
EUR 32,08 VersandVersand von Australien nach USAAnzahl: 1 verfügbar
Hardcover. Zustand: new. Hardcover. Biopharmaceutical R&D stands at a crossroads. Escalating development costs, persistent clinical attrition, heightened competitive pressures, mounting regulatory complexity, and uncertain commercial rewards have made ""doing more with less""; an inherently flawed strategy for success and sustai…nability. This one-of-a-kind book reframes the conversation, arguing that the true objective is not simply value creation, but value maximization under risk and uncertainty. By integrating decision analysis with enterprise portfolio management, it provides leaders with the intellectual and operational foundation required to make defensible, high-stakes investment decisions across drug discovery, clinical development, regulatory approval, and commercialization. Grounded in decades of real-world experience, the book builds on CREOPM, first introduced in 2012, as a pragmatic and maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of R&D organizations. Moving beyond weak data gathering resulting in single-point estimates and deterministic scorecards, it demonstrates how probabilistic modeling, efficient-frontier thinking, and integrated evaluation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking sustained competitiveness, transparent decision lineage, and measurable performance improvement in complex Biopharma environments. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.
